Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $163.21 Average Price Target from Brokerages
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong […]
More Stories
StockNews.com Begins Coverage on Macy’s (NYSE:M)
StockNews.com assumed coverage on shares of Macy’s (NYSE:M – Free Report) in a research report report published on Wednesday morning....
Chesapeake Energy (NASDAQ:EXE) Given New $97.00 Price Target at Citigroup
Chesapeake Energy (NASDAQ:EXE – Free Report) had its price target hoisted by Citigroup from $90.00 to $97.00 in a report...
SM Energy (NYSE:SM) PT Raised to $54.00
SM Energy (NYSE:SM – Free Report) had its price target increased by JPMorgan Chase & Co. from $50.00 to $54.00...
Coinbase Global (NASDAQ:COIN) Stock Rating Reaffirmed by JMP Securities
JMP Securities reaffirmed their market outperform rating on shares of Coinbase Global (NASDAQ:COIN) in a research report report published on...
Hyong Kim Sells 22,460 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock
Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) insider Hyong Kim sold 22,460 shares of the business’s stock in a...
W. R. Berkley (NYSE:WRB) PT Raised to $63.00 at Wells Fargo & Company
W. R. Berkley (NYSE:WRB – Get Free Report) had its price objective lifted by equities researchers at Wells Fargo &...